Biotech · Private company · Allen, TX, US
Nugenerex Immuno-Oncology, Inc.
SEC CIK 0001804585
Track this companyFree. Adds Nugenerex Immuno-Oncology, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials10 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- AE37 Peptide vaccinePhase 2 · Triple-negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Triple-negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast CancerPHASE2 · UNKNOWN · started May 3, 2019ClinicalTrials.gov NCT04024800 · fetched Nov 12, 2026